

Special Issue

Case Reports of Autoimmune Diseases

Message from the Guest Editor

For this Special Issue, we are inviting manuscripts in “Case report” format with clinical interest related to this topic that shall allow further advancements in our knowledge of autoimmunity. We are particularly interested in pathophysiological studies, but diagnostic or therapeutic approaches will also be welcome.

Guest Editor

Dr. Juan Luis Fernandez-Morera

1. Sección de Endocrinología y Nutrición, Hospital V. Álvarez Buylla, Calle Vistalegre, 2, 33611 Mieres, Asturias, Spain
2. Epigenética del Cáncer y Nanomedicina, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Avda. Hospital Universitario s/n, 33011 Oviedo, Spain

Deadline for manuscript submissions

closed (31 December 2022)



Reports

an Open Access Journal
by MDPI

Impact Factor 0.6
Indexed in PubMed



mdpi.com/si/69667

Reports
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
reports@mdpi.com

[mdpi.com/journal/
reports](https://mdpi.com/journal/reports)





Reports

an Open Access Journal
by MDPI

Impact Factor 0.6
Indexed in PubMed



[mdpi.com/journal/
reports](https://mdpi.com/journal/reports)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Toshio Hattori

1. Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka 420-0881, Shizuoka, Japan
2. International Research Institute of Disaster Science, Tohoku University, Sendai 980-8577, Miyagi, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), FSTA, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.7 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).